150 related articles for article (PubMed ID: 22995987)
1. The clinical relevance of rising CA-125 levels within the normal range in patients with uterine papillary serous cancer.
Frimer M; Hou JY; McAndrew TC; Goldberg GL; Shahabi S
Reprod Sci; 2013 Apr; 20(4):449-55. PubMed ID: 22995987
[TBL] [Abstract][Full Text] [Related]
2. Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma.
Schmidt M; Segev Y; Sadeh R; Suzan E; Feferkorn I; Kaldawy A; Kligun G; Lavie O
Int J Gynecol Cancer; 2018 Sep; 28(7):1311-1317. PubMed ID: 29958235
[TBL] [Abstract][Full Text] [Related]
3. Preoperative CA-125 predicts extra-uterine disease and survival in uterine papillary serous carcinoma patients.
Roelofsen T; Mingels M; Hendriks JC; Samlal RA; Snijders MP; Aalders AL; Bulten J; van Ham MA; Massuger LF
Int J Biol Markers; 2012 Oct; 27(3):e263-71. PubMed ID: 22865295
[TBL] [Abstract][Full Text] [Related]
4. Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma.
Gupta D; Gunter MJ; Yang K; Lee S; Zuckerwise L; Chen LM; Goldberg GL; Huang GS
Int J Gynecol Cancer; 2011 Apr; 21(3):529-34. PubMed ID: 21436701
[TBL] [Abstract][Full Text] [Related]
5. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma.
Olawaiye AB; Rauh-Hain JA; Withiam-Leitch M; Rueda B; Goodman A; del Carmen MG
Gynecol Oncol; 2008 Sep; 110(3):293-8. PubMed ID: 18644620
[TBL] [Abstract][Full Text] [Related]
6. Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma.
Abramovich D; Markman M; Kennedy A; Webster K; Belinson J
J Cancer Res Clin Oncol; 1999 Dec; 125(12):697-8. PubMed ID: 10592103
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of hematological parameters in women with uterine serous papillary carcinoma (USPC).
Younes G; Segev Y; Begal J; Auslender R; Goldberg Y; Amit A; Lavie O
Eur J Obstet Gynecol Reprod Biol; 2016 Apr; 199():16-20. PubMed ID: 26894377
[TBL] [Abstract][Full Text] [Related]
8. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.
Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
Gynecol Oncol; 1999 Aug; 74(2):272-7. PubMed ID: 10419744
[TBL] [Abstract][Full Text] [Related]
9. Analysis of clinical and pathological characteristics, treatment methods, survival, and prognosis of uterine papillary serous carcinoma.
Solmaz U; Ekin A; Mat E; Gezer C; Dogan A; Biler A; Peker N; Hasdemir PS; Sanci M
Tumori; 2016 Dec; 102(6):593-599. PubMed ID: 27514313
[TBL] [Abstract][Full Text] [Related]
10. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
Kelly MG; O'malley DM; Hui P; McAlpine J; Yu H; Rutherford TJ; Azodi M; Schwartz PE
Gynecol Oncol; 2005 Sep; 98(3):353-9. PubMed ID: 16005947
[TBL] [Abstract][Full Text] [Related]
11. Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?
Kwon JS; Abrams J; Sugimoto A; Carey MS
Int J Gynecol Cancer; 2008; 18(4):820-4. PubMed ID: 17892450
[TBL] [Abstract][Full Text] [Related]
12. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.
Greggi S; Mangili G; Scaffa C; Scala F; Losito S; Iodice F; Pisano C; Montoli S; Viganò R; Pirozzi G; Giannarelli D
Int J Gynecol Cancer; 2011 May; 21(4):661-7. PubMed ID: 21412164
[TBL] [Abstract][Full Text] [Related]
13. Uterine papillary serous cancer: a review of the literature.
del Carmen MG; Birrer M; Schorge JO
Gynecol Oncol; 2012 Dec; 127(3):651-61. PubMed ID: 23000148
[TBL] [Abstract][Full Text] [Related]
14. Uterine papillary serous carcinoma: state of the state.
Naumann RW
Curr Oncol Rep; 2008 Nov; 10(6):505-11. PubMed ID: 18928665
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of thrombocytosis in uterine papillary serous carcinomas.
Lerner DL; Walsh CS; Cass I; Karlan BY; Li AJ
Gynecol Oncol; 2007 Jan; 104(1):91-4. PubMed ID: 16934317
[TBL] [Abstract][Full Text] [Related]
16. Clinical Significance of Positive Pelvic Washings in Uterine Papillary Serous Carcinoma Confined to an Endometrial Polyp.
Hanley KZ; Fadare O; Fisher KE; Atkins KA; Mosunjac MB
Int J Gynecol Pathol; 2016 May; 35(3):249-55. PubMed ID: 26535985
[TBL] [Abstract][Full Text] [Related]
17. CA 125 may not reflect disease status in patients with uterine serous carcinoma.
Price FV; Chambers SK; Carcangiu ML; Kohorn EI; Schwartz PE; Chambers JT
Cancer; 1998 May; 82(9):1720-5. PubMed ID: 9576294
[TBL] [Abstract][Full Text] [Related]
18. Cytologic findings of cervicovaginal smears in women with uterine papillary serous carcinoma.
Park JY; Kim HS; Hong SR; Chun YK
J Korean Med Sci; 2005 Feb; 20(1):93-7. PubMed ID: 15716611
[TBL] [Abstract][Full Text] [Related]
19. A novel model to predict cancer-specific survival in patients with early-stage uterine papillary serous carcinoma (UPSC).
Chen L; Liu X; Li M; Wang S; Zhou H; Liu L; Cheng X
Cancer Med; 2020 Feb; 9(3):988-998. PubMed ID: 31846222
[TBL] [Abstract][Full Text] [Related]
20. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
